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Background: Estimated rate of Hcv-infected patients in
Belarus consistent of 1.5-2.5% of population, The
introduction of directly acting antiviral agents (DAA) fоr
treatment of HCV-infection into clinical practice makes
it possible to hope fоr eradication of Hcv infection in
the future.
Aim of the study: to evaluated the efficacy of
sofosbuvir-containing regimens for treatment of Hcv-
infected patients living in Grodno region of Веlаrus
Material and methods: Clinical and laboratory data of
69 HCV-infected patients living in the Grodno rеgiоп of
the Repub|ic of Belarus, who received DAA therapy,
wеrе analyzed. patients infected with genotypes ]- and
3 of the Hcv have received the scheme sofosbuvir and
Daklatosvir. Patients infected with the 2 genotype -
Sofosbuvir and RiЬачiriп in standard dosages. The
duration of the regimens was 12 weeks for most
patients in the group, in patients with advanced fibrosis
and liчеr cirrhosis the сочrsе of treatment was
extended to 16 weeks. Patients with HBV co-infection
wеrе excluded from the group, co-infection of HlV /
HCV occurred in 2 patients. "Statistica" 10,0 was used,
The data are presented in Ме (Q25; Q75).
Results: Among the patients there wеrе 39 (56,5%)
Women and 30 (43.5%) men. The age of the patients
was 48 (з5, 57) years. The duration of observation for
HCV infection in patients of group was 1 (3-8) уеаr, The
experience of disease mоrе than 10 years was
established iп t2 (l7,4%). According to genotypes of
Hcv, the patients wеrе distributed as follows: the
genotype 1 of HCV was in 48 (69.6%), the genotype 2 -
in 10 (14.5%), genotype 3 - in 9 (13.О%); lп 2 cases, а
mixed infection of 1 and 2 genotype was established,
The viral load of the HcV рriоr to initiation of thеrару
was 610 29S,O (300 500.0; 3 972 015) lU/ml. A|AT was
64 (З9.6, 115.0) U/L, AsAT - 67.2 0а; З75) U/L,
Advanced fibrosis (3-4 stages Ьу Metavir), including
'liчеr cirrhosis of class А, was in 5 patients.
45
Рrеlimiпаrу therapy with interferon alpha in
combination with riЬачiriп was реrfоrmеd in З0 (43,5%)
patientS,
Comorbidity оссчrrеd in mоrе than 50% of patients, At
the same time, 5 patients had malignant tumors of
different localization, including 1 case of hepatocellular
саrсiпоmа (НСС).
All patients in the group achieved а virological rеsропsе
(VR) proven Ьу negative result of HcV RNA in serum
detection оп end of thеrару. None of the patients
indicated significant side effects. Late relapse of Hcv-
infection was fixed in 3 patients (4,з%|, so sustained
virologicaI rеsропsе at 24 weeks (SVR24) was
documented iП95,7Yо CaSes. Among 3 patients without
SVR24 two patients had genotype 2 and опе had
genotype 1, НlV infection was in 1 case, liver cirhhosis -
in 1 case,
ConcIusion: The DAA therapy demonstrated 95,7% of
SVR24 iп the analyzed group of patients, despite the
рrеSепсе iп the group of so-called difficult patients
infected with the 1st Hcv genotype, who had advanced
liver fibrosis and did not rеsропd to previous interferon
containing regimens.
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